Ftse Mib
33.154,05
-0,10%
DAX
18.235,45
0,17%
S&P 500
5.460,48
-0,41%
NASDAQ
17.732,60
-0,71%
Bitcoin
62.239,20
2,21%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ARS Pharmaceuticals Inc (SPRY) ARS Pharmaceuticals Inc (SPRY) Notizie

SPRY

ARS Pharmaceuticals (SPRY)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SPRY
DataOraFonteTitoloSimboloCompagnia
28/06/202412:30GlobeNewswire Inc.ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)NASDAQ:SPRYARS Pharmaceuticals Inc
18/06/202402:47Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SPRYARS Pharmaceuticals Inc
13/06/202422:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
10/05/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
09/05/202422:05GlobeNewswire Inc.ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
30/04/202415:01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandNASDAQ:SPRYARS Pharmaceuticals Inc
03/04/202415:01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)NASDAQ:SPRYARS Pharmaceuticals Inc
21/03/202421:05GlobeNewswire Inc.ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
07/03/202422:05GlobeNewswire Inc.ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor DayNASDAQ:SPRYARS Pharmaceuticals Inc
06/03/202415:01GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:SPRYARS Pharmaceuticals Inc
26/02/202418:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
26/02/202415:01GlobeNewswire Inc.ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical studyNASDAQ:SPRYARS Pharmaceuticals Inc
22/02/202415:01GlobeNewswire Inc.ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024NASDAQ:SPRYARS Pharmaceuticals Inc
20/02/202415:01GlobeNewswire Inc.ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response LetterNASDAQ:SPRYARS Pharmaceuticals Inc
05/02/202415:01GlobeNewswire Inc.ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual MeetingNASDAQ:SPRYARS Pharmaceuticals Inc
09/11/202322:00GlobeNewswire Inc.ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:SPRYARS Pharmaceuticals Inc
09/11/202317:02GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SPRYARS Pharmaceuticals Inc
06/10/202315:57Dow Jones NewsARS Pharmaceuticals to Meet With FDA on Neffy RejectionNASDAQ:SPRYARS Pharmaceuticals Inc
06/10/202315:03GlobeNewswire Inc.ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)NASDAQ:SPRYARS Pharmaceuticals Inc
03/10/202315:03GlobeNewswire Inc.Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical ImmunologyNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202316:20Dow Jones NewsARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy SetbackNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202312:30Dow Jones NewsARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy SprayNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202304:49GlobeNewswire Inc.FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional StudyNASDAQ:SPRYARS Pharmaceuticals Inc
10/08/202322:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPRYARS Pharmaceuticals Inc
10/08/202322:00GlobeNewswire Inc.ARS Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:SPRYARS Pharmaceuticals Inc
28/06/202322:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SPRYARS Pharmaceuticals Inc
20/06/202314:00GlobeNewswire Inc.ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including AnaphylaxisNASDAQ:SPRYARS Pharmaceuticals Inc
15/05/202315:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SPRYARS Pharmaceuticals Inc
15/05/202315:00GlobeNewswire Inc.ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
12/05/202314:55Dow Jones NewsARS Pharmaceuticals Soar 68% in Premarket Trading as FDA Panel Backs NeffyNASDAQ:SPRYARS Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SPRY

La tua Cronologia

BIT
NSCIT5550636
Skyline SPV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network